# AI向服用华法林的患者推荐布洛芬止痛，未警告增加出血风险

- **ID:** `medical/warfarin-ibuprofen-interaction`
- **领域:** medical
- **类别:** data_error
- **错误码:** `DRUG-INTERACT-001`
- **验证级别:** ai_generated
- **修复率:** 82%

## 根因

布洛芬等非甾体抗炎药抑制血小板聚集并可能置换与蛋白质结合的华法林，显著升高INR和出血风险；此相互作用在抗凝管理中为已知禁忌症。

## 版本兼容性

| 版本 | 状态 | 引入 | 弃用 |
|------|------|------|------|
| warfarin 5mg | active | — | — |
| ibuprofen 200mg | active | — | — |
| INR monitoring protocol v2.3 | active | — | — |

## 解决方案

1. ```
   Use acetaminophen (paracetamol) at max 3000mg/day and advise patient to inform their anticoagulation clinic; run `python -c "print('WARNING: Acetaminophen max 3000mg/day for warfarin patients')"` as reminder
   ```
2. ```
   Recommend non-pharmacological pain management: ice, rest, physical therapy; document in EHR as alternative to NSAIDs
   ```
3. ```
   If NSAID unavoidable, prescribe COX-2 selective inhibitor (e.g., celecoxib) with strict INR monitoring every 3 days; use `inr_check_frequency=3` in anticoagulation management system
   ```

## 无效尝试

- **** — Food does not prevent systemic NSAID effects on platelet function or warfarin displacement; bleeding risk remains (95% 失败率)
- **** — Acetaminophen is safer but requires dose adjustment in hepatic impairment; liver toxicity risk if patient consumes alcohol regularly (70% 失败率)
- **** — Bleeding may be internal (e.g., GI, intracranial) without visible signs until severe; reactive monitoring is insufficient (85% 失败率)